Mark Liss, MD
Gastroenterology · New Rochelle, NYNPI 1902906142
Payments from drug & device makers
Across 9 payments — averaging $32.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$124
- Takeda Pharmaceuticals U.S.A., Inc.$42
- Ironwood Pharmaceuticals, Inc$25
- Madrigal Pharmaceuticals$23
- Lilly USA, LLC$22
- Merck$22
- plus $36 from 2 others
What the payments were for
- Food & beverage$293100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Ironwood Pharmaceuticals, Inc | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Merck | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Novo Nordisk | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XELJANZ$124
How this compares
$293 in reported general payments places this provider in the 20th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 12 | $290,176 |
| LinzessLinaclotide | 44 | $38,483 |
| Mesalamine | 41 | $25,823 |
| Sucralfate | 26 | $2,482 |
| Omeprazole | 112 | $1,373 |
| Famotidine | 91 | $1,179 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 19 | $1,082 |
| CholestyramineCholestyramine (With Sugar) | 21 | $899 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 63 | $675 |
| Pantoprazole Sodium | 60 | $506 |
| Mercaptopurine | 13 | $376 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 14 | $216 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in New Rochelle
- Michael GerdisYonkers$11.9M
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Igor GrosmanBrooklyn$2.8M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.